Physician profile
Howard Silversmith
NPI 1730146614
$659.69
in general payments reported to CMS, 2019-2025
15 companies · $144 in 2025
The $144 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $271 · 2020: $51.89 · 2021: $46.97 · 2022: $24.99 · 2023: $100 · 2024: $20.03 · 2025: $144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $264.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $264.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $99.83 | 2019-2024 | Vaxelis, Gardasil 9, M-M-R II |
| Tris Pharma INC | $83.63 | 2019-2023 | Dyanavel Xr |
| Glaxosmithkline, LLC. | $67.23 | 2019-2020 | |
| Collegium Pharmaceutical, INC. | $61.14 | 2025 | Jornay Pm |
| Exeltis, USA INC. | $57.69 | 2025 | Slynd |
| Kaleo, INC. | $43.20 | 2023 | Auvi-Q |
| Pfizer INC. | $43.04 | 2019 | |
| Ironshore Pharmaceuticals INC. | $42.20 | 2019 | |
| Sobi, INC | $30.08 | 2021 | |
| Dermira, INC. | $29.35 | 2019 | |
| Ars Pharmaceuticals Operations, INC. | $25.33 | 2025 | Neffy |
| Neurelis, INC. | $24.99 | 2022 | |
| Neos Therapeutics, LP | $18.97 | 2019 | |
| Genentech USA, INC. | $16.89 | 2021 | |
| Shire North American Group INC | $16.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Silversmith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.